RGLS - Regulus Therapeutics Releases Early Data From Of Investigational For Rare Type Of Kidney Disease | Benzinga
Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) trial of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
ADPKD is an inherited condition that causes tiny fluid-filled sacs called cysts to develop in the kidneys.
In the first cohort, 12 subjects were randomized 3:1 to receive either 1 mg/kg of RGLS8429 or placebo every ...